Insulet Co. (PODD) Director John A. Fallon Sells 9,000 Shares of Stock

Insulet Co. (NASDAQ:PODD) Director John A. Fallon sold 9,000 shares of Insulet stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $84.10, for a total transaction of $756,900.00. The sale was disclosed in a document filed with the SEC, which is available through this link.

Shares of Insulet Co. (PODD) traded up $0.62 on Friday, reaching $85.23. 511,279 shares of the company traded hands, compared to its average volume of 474,056. The company has a market cap of $4,940.47, a P/E ratio of -185.28 and a beta of 1.56. Insulet Co. has a 12-month low of $38.43 and a 12-month high of $85.71. The company has a quick ratio of 5.85, a current ratio of 6.24 and a debt-to-equity ratio of 3.57.

How to Become a New Pot Stock Millionaire

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The firm had revenue of $130.50 million during the quarter, compared to the consensus estimate of $125.16 million. Insulet had a negative return on equity of 29.73% and a negative net margin of 5.79%. The business’s revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.16) EPS. equities research analysts forecast that Insulet Co. will post -0.3 EPS for the current year.

A number of brokerages have issued reports on PODD. Zacks Investment Research raised shares of Insulet from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub raised shares of Insulet from a “hold” rating to a “buy” rating in a research note on Friday, March 9th. Oppenheimer set a $82.00 target price on shares of Insulet and gave the company a “hold” rating in a research note on Thursday, February 22nd. BMO Capital Markets initiated coverage on shares of Insulet in a research note on Monday, March 5th. They issued an “outperform” rating and a $90.00 price objective for the company. Finally, Stephens reaffirmed an “equal weight” rating and issued a $81.00 price objective (up previously from $60.00) on shares of Insulet in a research note on Thursday, February 22nd. Eight equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $73.24.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cerebellum GP LLC bought a new position in Insulet in the 4th quarter worth $122,000. Equitec Specialists LLC bought a new position in Insulet in the 4th quarter worth $145,000. James Hambro & Partners bought a new position in Insulet in the 4th quarter worth $165,000. C M Bidwell & Associates Ltd. bought a new position in Insulet in the 4th quarter worth $188,000. Finally, Diversified Trust Co bought a new position in Insulet in the 4th quarter worth $218,000.

TRADEMARK VIOLATION NOTICE: This story was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.com-unik.info/2018/03/17/insulet-co-podd-director-john-a-fallon-sells-9000-shares-of-stock.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit